Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Emisphere Technologies, Inc. today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen Technology.

16 Apr 2010

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

3M Drug Delivery Systems recently advanced its participation in the Asian market with a sponsorship of the Asia Pharma R&D Leaders 2010 event, held March 4 and 5 in Shanghai, China.

16 Apr 2010

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

Lauric-acid-filled nano-scale bombs for treating acne

A natural product found in both coconut oil and human breast milk - lauric acid -- shines as a possible new acne treatment thanks to a bioengineering graduate student from the UC San Diego Jacobs School of Engineering. The student developed a "smart delivery system" - published in the journal ACS Nano in March - capable of delivering lauric-acid-filled nano-scale bombs directly to skin-dwelling bacteria (Propionibacterium acnes) that cause common acne.

15 Apr 2010

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.

15 Apr 2010

Patheon adds development and manufacturing softgel capability in Cincinnati facility

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it is adding development and manufacturing softgel capability in its Cincinnati facility, providing the pharmaceutical industry a new contract provider for this popular drug delivery system.

15 Apr 2010

PSI acquires PEG-based technology

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena.

15 Apr 2010

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

15 Apr 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

13 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference

Celsion Corporation today announced that Dr. Ronnie T.P. Poon from the University of Hong Kong and lead principal investigator for the Asia Pacific region of the Phase I ThermoDox dose escalation trial will hold a press conference on Thursday, April 15, 2010 at 10:30 AM HKT (Wednesday, April 14, 2010 10:30 PM ET) to discuss the long-term follow-up of patients treated from April 2006 to December 2006.

12 Apr 2010

Study suggests new ways to improve anti-cancer chemotherapies

A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.

12 Apr 2010

NexMed expands San Diego facilities to accommodate pre-clinical research services

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has expanded its San Diego facilities to accommodate an increase in demand for its pre-clinical research services.

9 Apr 2010

Cephalon acquires Mepha

Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.

9 Apr 2010

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

Penwest Pharmaceuticals Co. today announced that it has signed a drug development and commercialization agreement with Alvogen, Inc. under which Penwest and Alvogen have agreed to identify and select up to five compounds for generic development. Penwest's TIMERx technology may be used for each compound selected.

9 Apr 2010

Generex Biotechnology, Seaside 88 close first tranche of 2 million shares for gross proceeds of $945,180

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a common stock purchase agreement with Seaside 88, LP, a private investment limited partnership. Seaside has committed to purchase up to 49,455,130 shares of Generex common stock.

9 Apr 2010

LSDF announces $15M in program grant to enhance diagnosis and treatment of cancer

The Life Sciences Discovery Fund today announced nearly $15 million in program grant awards to support collaborative research initiatives spearheaded by three Washington state life sciences organizations.

8 Apr 2010

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the United States Bankruptcy Code.

8 Apr 2010

Drug Delivery News and Research

Further Reading

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Lauric-acid-filled nano-scale bombs for treating acne

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Patheon adds development and manufacturing softgel capability in Cincinnati facility

PSI acquires PEG-based technology

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference

Study suggests new ways to improve anti-cancer chemotherapies

NexMed expands San Diego facilities to accommodate pre-clinical research services

Cephalon acquires Mepha

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

Generex Biotechnology, Seaside 88 close first tranche of 2 million shares for gross proceeds of $945,180

LSDF announces $15M in program grant to enhance diagnosis and treatment of cancer

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News